Focused On-demand Library for Protein regulator of cytokinesis 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

O43663

UPID:

PRC1_HUMAN

Alternative names:

Alternative UPACC:

O43663; A6NC44; B4DLR1; H9KV59; Q9BSB6

Background:

Protein Regulator of Cytokinesis 1 (PRC1) is a pivotal component in cell division, specifically in the process of cytokinesis. It functions by cross-linking antiparallel microtubules, facilitating the formation of the midzone essential for cell division. PRC1's role extends to the localization of KIF14 and the recruitment of PLK1 to the spindle, crucial for cell cycle progression. Its interaction with RACGAP1 and ECT2 underscores its importance in cytokinesis.

Therapeutic significance:

Understanding the role of Protein Regulator of Cytokinesis 1 could open doors to potential therapeutic strategies. Its involvement in critical cell division processes and its oncogenic potential in bladder cancer highlight its significance as a target for cancer therapy. By modulating PRC1 activity, it may be possible to develop novel treatments for cancer, emphasizing the need for further research into its mechanisms and interactions.